The price of Intra-Cellular Therapies Inc (NASDAQ:ITCI) shares last traded on Wall Street fell -0.06% to $127.07.
ITCI stock price is now 38.15% away from the 50-day moving average and 62.65% away from the 200-day moving average. The market capitalization of the company currently stands at $13.50B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $68 to $92, Piper Sandler Upgraded its rating from Neutral to Overweight for Intra-Cellular Therapies Inc (NASDAQ: ITCI). On January 03, 2024, Robert W. Baird recently initiated its ‘Outperform’ rating on the stock quoting a target price of $83, while ‘TD Cowen’ rates the stock as ‘Outperform’
In other news, Mates Sharon, Chairman and CEO sold 51,000 shares of the company’s stock on Dec 04 ’24. The stock was sold for $4,375,659 at an average price of $85.80. Upon completion of the transaction, the Chairman and CEO now directly owns 1,070,329 shares in the company, valued at $136.01 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 05 ’24, Chairman and CEO Mates Sharon sold 51,697 shares of the business’s stock. A total of $4,346,842 was realized by selling the stock at an average price of $84.08. This leaves the insider owning 1,070,329 shares of the company worth $136.01 million. A total of 6.53% of the company’s stock is owned by insiders.
During the past 12 months, Intra-Cellular Therapies Inc has had a low of $62.78 and a high of $128.00. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 7.66, and a quick ratio of 7.51. The fifty day moving average price for ITCI is $91.2494 and a two-hundred day moving average price translates $77.832 for the stock.
The latest earnings results from Intra-Cellular Therapies Inc (NASDAQ: ITCI) was released for 2024-09-30. The net profit margin was -14.07% and return on equity was -9.90% for ITCI. The company reported revenue of $175.38 million for the quarter, compared to $126.17 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 39.0 percent. For the current quarter, analysts expect ITCI to generate $193.96M in revenue.
